patient wih mild to moderate traumatic brain injury in ICU will be randomisly distributed
into two groups Group I (control group): Patients of this group receive placebo infusion for
72 hours. Group II (DEX group): Patients of this group receive 0.5 ug/kg/hr dexmedetomidine
continuous infusion for 72 hour Patient demographics, including age, sex, weight, primary
diagnosis, Acute Physiology and Chronic Health Evaluation (APACHE) II score and
postresuscitation Glasgow Coma Scale (GCS) score will be collected. CBF will be measured at
pre-sedation and after cessation of sedation (dexmedetomidine administration). The CMRe and
CMRe/CBF will also be calculated. Measurements of blood gas analysis and haemodynamic
parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP), MAP and heart rate
(HR)] will be collected at pre-sedation and after cessation of sedation (dexmedetomidine
administration).